Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation

The current treatment of chronic phase chronic myeloid leukemia (CML) consists of oral tyrosine kinase inhibitors (TKIs). However, high-risk CML may present with an aggressive course which may result in blastic crisis or a “difficult-to-manage” state with available treatments. The aim of this paper...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Uz, B., Bektas, O., Eliacık, E., Goker, H., Erbilgin, Y., Sayitoglu, M., Sayinalp, N., Aksu, S., Buyukasik, Y., Ozcebe, O., Haznedaroglu, I. C.
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi Publishing Corporation 2011
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3420724/
https://ncbi.nlm.nih.gov/pubmed/22937303
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2011/263725
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados